Repros Therapeutics
Inc.^ RPRX today announced that it has entered into definitive
agreements with certain institutional investors, including certain existing
shareholders, to sell an aggregate of 2,463,538 shares of common stock, par
value $0.001 per share in a registered direct offering for
gross proceeds of approximately $11.1 million, before deducting placement
agent's fees and estimated offering expenses. The investors have agreed to
purchase the shares of Common Stock for a price of $4.50 per share.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in